On May 21, 2021, the U.S. Food and Drug Administration approved the Guardant360® CDx liquid biopsy test as the first and only companion diagnostic for amivantamab-vmjw.
The Guardant360 CDx test will be used for tumor mutation profiling or comprehensive genomic profiling to identify patients with locally advanced or metastatic non-small cell lung cancer who harbor the EGFR exon 20 insertion mutation and may benefit from targeted treatment with amivantamab-vmjw after progressing on or after platinum-based chemotherapy.
Read Guardant Health's announcement.
Posted 5/24/2021
In recognition of Leukemia and Lymphoma Awareness Month, ACCC compiled a group of resources to help care teams navigate two of the most commonly diagnosed adult leukemias: acute myeloid leukemia and chronic lymphocytic leukemia.
